Enable job alerts via email!
Boost your interview chances
Create a job specific, tailored resume for higher success rate.
An established industry player is seeking a Senior Medical Director to drive clinical development for innovative therapies in neurology and neuropsychiatry. This high-impact role involves leadership across clinical trials, strategic planning, and collaboration with regulatory bodies and thought leaders. The position offers a hybrid working model, allowing flexibility while ensuring a strong presence in the office. Join a company committed to making a meaningful impact on patients' lives through groundbreaking research and development, all while fostering a culture of diversity and inclusion. If you're passionate about advancing neuroscience, this opportunity is for you.
Job Description
This is a high impact position with great visibility and collaboration across multiple departments and all levels of the Alkermes organization. This position will have critical responsibilities in the clinical development group involved in the development of therapies for neurology and neuropsychiatric indications across early- and late-stage programs, contributing to Alkermes' expansion of Research and Development efforts in neuroscience.
Additionally, the Senior Medical Director will participate in internal strategy regarding future therapeutic priorities and modalities and interact extensively with key global regulatory authorities, industry and scientific organizations, as well as external key thought leaders.
Alkermes has recently adopted a hybrid working environment to support and meet the needs of employees and this role will operate in a flexible environment with 60% of time in the office and 40% from home. This position is eligible for the hybrid workplace model, requiring work to be completed onsite at our Waltham, MA office at least 3 days per week. This role is not eligible for fully remote work.
About Us
Why join Team Alkermes?
Alkermes applies its deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. A fully-integrated, global biopharmaceutical company, headquartered in Ireland with U.S. locations in Massachusetts and Ohio, we are committed to pursuing great science, driven by deep compassion to make a real impact in the lives of patients. Alkermes has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for various neurological disorders, including narcolepsy.
Beyond our important mission of developing medicines to address unmet patient needs, we actively seek to foster a culture of diversity, inclusion and belonging throughout our business. We strive to ensure that all voices are respected and valued, recognizing that our diversity of thought, background and perspective makes us stronger. We are proud to have been recognized as an employer of choice by many national organizations, including being certified as a Great Place to Work in the U.S. in 2024, honored as a Healthiest Employer in both Ohio and Massachusetts in 2023, a Best Place for Working Parents in 2023, and to have received the Bell Seal at the Platinum level for Workplace Mental Health by Mental Health America for three consecutive years (2021-2023).
Alkermes, Inc. is an equal employment opportunity employer and does not discriminate against any qualified applicant or employee because of race, creed, color, age, national origin, ancestry, religion, gender, sexual orientation, gender expression and identity, disability, genetic information, veteran status, military status, application for military service or any other characteristic protected by local, state or federal law. Alkermes also complies with all work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Alkermes is an E-Verify employer.